Trial Profile
Effects of Erythropoietin on Cognitive Functions and Neural Activity in Cognitively Impaired Remitted Patients With Bipolar Disorder or Recurrent Depressive Disorder and Healthy People: Study Protocol for a Randomized, Controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Bipolar disorders; Cognition disorders; Depressive disorders
- Focus Therapeutic Use
- Acronyms Pre TEC-EPO; PRETEC-EPO
- 29 Jul 2022 Status changed from recruiting to completed.
- 07 Apr 2022 Planned End Date changed from 1 Feb 2021 to 1 Oct 2022.
- 07 Apr 2022 Planned primary completion date changed from 1 Feb 2021 to 1 Oct 2022.